Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

Ka Lung Wu; Wessel van Wieringen; Edo Vellenga; Sonja Zweegman; Henk M Lokhorst; Pieter Sonneveld

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

Haematologica. 2005 Jul;90(7):996-7.

Authors

Ka Lung Wu, Wessel van Wieringen, Edo Vellenga, Sonja Zweegman, Henk M Lokhorst, Pieter Sonneveld

PMID: 15996946

Abstract

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Antineoplastic Agents / toxicity
Boronic Acids / therapeutic use*
Boronic Acids / toxicity*
Bortezomib
Combined Modality Therapy
Herpes Zoster / etiology
Humans
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Pyrazines / therapeutic use*
Pyrazines / toxicity*
Recurrence
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents
Boronic Acids
Pyrazines
Bortezomib